506 related articles for article (PubMed ID: 31950135)
1. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
5. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
7. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
9. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
10. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
[TBL] [Abstract][Full Text] [Related]
12. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
13. Genome-Edited T Cell Therapies.
Ottaviano G; Qasim W
Hematol Oncol Clin North Am; 2022 Aug; 36(4):729-744. PubMed ID: 35773047
[TBL] [Abstract][Full Text] [Related]
14. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.
Ureña-Bailén G; Lamsfus-Calle A; Daniel-Moreno A; Raju J; Schlegel P; Seitz C; Atar D; Antony JS; Handgretinger R; Mezger M
Brief Funct Genomics; 2020 May; 19(3):191-200. PubMed ID: 31844895
[TBL] [Abstract][Full Text] [Related]
16. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
17. Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
Wälchli S; Sioud M
Methods Mol Biol; 2020; 2115():407-417. PubMed ID: 32006413
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
Chen M; Xu J; Zhou Y; Zhang S; Zhu D
Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
[TBL] [Abstract][Full Text] [Related]
20. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]